ABBV · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-08-03 · Importance 34 · Surprise 60 · In source text
AbbVie recorded $1.1 billion of payments for other acquisitions and investments, net of cash acquired, during the six months ended June 30, 2026. AbbVie recognized a $650 million upfront IPR&D charge for its license agreement with RemeGen Co., Ltd. Subsequent to June 30, 2026, AbbVie entered into a $10.0 billion 364-day senior unsecured term loan facility to support the proposed acquisition of Apogee. AbbVie also acquired a device manufacturing facility in Arizona, with the transaction closing in July 2026.
Key facts
- Subsequent to June 30, 2026, in connection with the proposed acquisition of Apogee, AbbVie entered into a $10.0 billion 364-day senior unsecured term loan facility; no amounts had been drawn as of the date of filing of this 10-Q. source
- AbbVie entered into an agreement to acquire a device manufacturing facility in Arizona which closed in July 2026. source
- Investing cash flows for the six months ended June 30, 2026 included payments for other acquisitions and investments, net of cash acquired of $1.1 billion and capital expenditures of $587 million. source
- Acquired IPR&D and milestones expense for the six months ended June 30, 2026 included an upfront charge of $650 million related to a license agreement with RemeGen Co., Ltd.; total acquired IPR&D and milestones for six months ended June 30, 2026: $1,071 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.4% | Investing cash flows for the six months ended June 30, 2026 included payments for other acquisitions and investments, net of cash acquired… |
| assets | positive | committed | — | AbbVie entered into an agreement to acquire a device manufacturing facility in Arizona which closed in July 2026. |